NEW YORK (GenomeWeb News) – Agendia said today it has raised $65 million in a private round of equity financing.

The funds will be used to further expand the company's Symphony suite of breast cancer tests and the continued development of "our personalized medicine pipeline," Agendia CEO David Macdonald said in a statement. The company recently launched its Symphony suite in a formalin-fixed, paraffin-embedded format, and will soon launch its ColoPrint recurrence test for stage II colon cancer prognosis and prediction, he added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.